Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pudafensine
- Development stage
- Phase 2
- Lead developer
- Initiator Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Pudafensine (IPED2015) is a small molecule drug candidate developed by Initiator Pharma for the treatment of organic erectile dysfunction (ED). It is specifically designed for patients who do not respond adequately to current phosphodiesterase type 5 (PDE5) inhibitors like sildenafil or tadalafil. Pudafensine acts as a triple monoamine reuptake inhibitor (TRI), preferentially binding to and inhibiting the dopamine transporter (DAT), noradrenaline transporter (NAT), and serotonin transporter (SERT). This mechanism increases synaptic levels of monoamines, particularly dopamine in the brain, which initiates the erectile response centrally. Additionally, the drug exerts a direct peripheral effect on erectile tissue by causing the relaxation of erectile smooth muscle. Pudafensine is formulated as an oral tablet and has successfully completed Phase IIb clinical trials, demonstrating statistically significant efficacy in ED endpoints with a favorable safety profile.
- Brand names
- pudafensine
- Other names
- 7-[(Exo-8-azabicyclo[3.2.1]octan-3-yl)oxy]-3-methoxy-chromen-2-one
02
Targets
SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)
Beyond the preview
Go deeper on pudafensine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pudafensine.